A 58-year-old man with a 40-pack-year smoking history presents with persistent cough and hemoptysis for 3 weeks. Chest X-ray shows a 3 cm irregular opacity in the left upper lobe with hilar lymphadenopathy. He is otherwise stable with normal oxygen saturation. Which imaging modality is most appropriate for staging and assessing resectability?

Explanation

## Clinical Scenario Analysis This patient has imaging findings highly suspicious for lung cancer: a 3 cm irregular opacity with hilar lymphadenopathy, in a heavy smoker with hemoptysis. The question specifically asks for the **most appropriate modality for staging AND assessing resectability**. ## Investigation of Choice: PET-CT with 18F-FDG **Key Point:** PET-CT with 18F-FDG is the **gold standard** for staging non-small cell lung cancer (NSCLC) and is the single most appropriate modality when both staging and resectability assessment are required together. It integrates metabolic and anatomical information in one study. ### Why PET-CT is Optimal for Lung Cancer Staging and Resectability | Parameter | PET-CT Advantage | |-----------|-----------------| | **Mediastinal lymph nodes** | Detects metabolically active nodes regardless of size (superior to CT alone) | | **Distant metastases** | Whole-body survey — adrenal, bone, contralateral lung, liver | | **Primary tumor** | FDG avidity confirms malignant nature | | **Resectability** | Identifies occult N2/N3 disease and M1 disease that would preclude surgery | | **Upstaging/downstaging** | Changes management in ~30% of cases vs CT alone | | **Radiation planning** | Defines biological target volume | **High-Yield:** Current NCCN, ESMO, and Indian guidelines recommend **PET-CT as the preferred staging modality** for potentially resectable NSCLC. It detects occult metastases that CT misses, directly impacting the decision to operate. ### PET-CT vs CT Alone for Staging - CT alone has ~60% sensitivity for mediastinal nodal staging; PET-CT has ~80–85% sensitivity and ~90% specificity. - PET-CT changes the surgical plan in approximately 20–30% of patients compared to CT alone. - A negative PET-CT mediastinum in a peripheral T1 tumor may allow direct surgery; a positive PET-CT mediastinum mandates tissue confirmation (EBUS/mediastinoscopy). **Clinical Pearl (Harrison 21e, Ch 105):** For patients with suspected resectable lung cancer, integrated PET-CT is recommended over CT alone because it simultaneously assesses local, regional, and distant disease — all determinants of resectability — in a single examination. ## Why Other Modalities Are Secondary or Inappropriate **HRCT chest with contrast (Option B):** HRCT is the essential first anatomical study and is always performed, but it cannot assess metabolic activity of lymph nodes or detect occult distant metastases. Lymph node size on CT is an unreliable criterion (false-positive enlarged reactive nodes; false-negative small malignant nodes). When the question asks for the *most appropriate* modality for **staging AND resectability**, PET-CT supersedes CT alone. **MRI chest (Option C):** Useful for specific indications — superior sulcus (Pancoast) tumors, cardiac/pericardial invasion, brachial plexus involvement — but not first-line for routine lung cancer staging. Longer acquisition time, less available, inferior for pulmonary parenchyma. **Repeat CXR in 2 weeks (Option D):** Entirely inappropriate. CXR cannot stage lung cancer, assess mediastinal invasion, evaluate lymph nodes, or detect distant metastases. Delaying diagnosis in a patient with likely lung cancer is harmful. **Mnemonic:** **PET STAGES** — PET-CT for Primary tumor, Entire nodal map, Thoracic and distant metastases, Adrenal/bone, Guides surgery, Excludes occult disease, Single study. [cite: Harrison 21e Ch 105; NCCN Guidelines NSCLC v2024; Grainger & Allison's Diagnostic Radiology 6e]